Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size

  • Jimenez-Leon, Maria Reyes|||0000-0003-2723-319X
  • Gasca-Capote, Carmen|||0000-0002-7211-8599
  • Roca-Oporto, Cristina|||0000-0003-0079-5491
  • Espinosa, Nuria|||0000-0003-2249-2352
  • Sobrino, Salvador
  • Fontillon-Alberdi, Maria|||0000-0003-4031-8067
  • Gao, Ce
  • Roseto, Isabelle
  • Gladkov, Gregory
  • Rivas-Jeremias, Inmaculada
  • Neukam, Karin
  • Sánchez Hernández, José Germán
  • Rigo Bonnin, Raül|||0000-0001-5511-074X
  • Cervera-Barajas, Antonio J.
  • Mesones, Rosario
  • García, Federico
  • Alvarez-Rios, Ana Isabel
  • Bachiller, Sara
  • Vitalle, Joana
  • Perez-Gomez, Alberto
  • Camacho-Sojo, María Inés
  • Gallego, Isabel
  • Brander, Christian|||0000-0002-0548-5778
  • McGowan, Ian
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Viciana, Pompeyo|||0000-0001-5606-0166
  • Yu, Xu
  • Lichterfeld, Mathias
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
BACKGROUND. We evaluated the safety and viral rebound, after analytical treatment interruption (ATI), of vedolizumab and ART in recent HIV-1 infection. We used this model to analyze the effect of α4β7 on the HIV-1 reservoir size. METHODS. Participants started ART with monthly vedolizumab infusions, and ATI was performed at week 24. Biopsies were obtained from ileum and cecum at baseline and week 24. Vedolizumab levels, HIV-1 reservoir, flow cytometry, and cell-sorting and antibody competition experiments were assayed. RESULTS. Vedolizumab was safe and well tolerated. No participant achieved undetectable viremia off ART 24 weeks after ATI. Only a modest effect on the time to achieve more than 1,000 HIV-1 RNA copies/mL and the proportion of participants off ART was observed, being higher in the vedolizumab group compared with historical controls. Just before ATI, α4β7 expression was associated with HIV-1 DNA and RNA in peripheral blood and with PD1 and TIGIT levels. Importantly, a complete blocking of α4β7 was observed on peripheral CD4 T cells but not in gut (ileum and cecum), where α4β7 blockade and vedolizumab levels were inversely associated with HIV-1 DNA. CONCLUSION. Our findings support α4β7 as an important determinant in HIV-1 reservoir size, suggesting the complete α4β7 blockade in tissue as a promising tool for HIV-cure combination strategies. TRIAL REGISTRATION. ClinicalTrials.gov NCT03577782. FUNDING. This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, "a way to make Europe," research contracts FI17/00186 and FI19/00083 and research projects PI18/01532, PI19/01127, PI22/01796), Conserjería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (research projects P20/00906), the Red Temática de Investigación Cooperativa en SIDA (RD16/0025/0020), and the Spanish National Research Council.
Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control

  • Moyano, Ana
  • Blanch Lombarte, Oscar
  • Tarancón Diez, Laura
  • Pedreño Lopez, Nuria
  • Arenas Busto, Miguel
  • Alvaro, Tamara
  • Casado, Concepción
  • Olivares, Isabel
  • Vera, Mar
  • Rodríguez, Carmen
  • del Romero, Jorge
  • López Galíndez, Cecilio
  • Ruiz Mateos, Ezequiel
  • Prado, Julia G.
  • Pernas, María
Background Long-Term Non-Progressors (LTNPs) are untreated Human Immunodeficiency virus type 1 (HIV-1) infected individuals able to control disease progression for prolonged periods. However, the LTNPs status is temporary, as viral load increases followed by decreases in CD4 + T-cell counts. Control of HIV-1 infection in LTNPs viremic controllers, have been associated with effective immunodominant HIV-1 Gag-CD8 + T-cell responses restricted by protective HLA-B alleles. Individuals carrying HLA-B*14:02 control HIV-1 infection is related to an immunodominant Env-CD8 + T-cell response. Limited data are available on the contribution of HLA-B*14:02 CD8 + T -cells in LTNPs. Results In this study, we performed a virological and immunological detailed analysis of an HLA-B*14:02 LNTP individual that lost viral control (LVC) 27 years after HIV-1 diagnosis. We analysed viral evolution and immune escape in HLA-B*14:02 restricted CD8 + T -cell epitopes and identified viral evolution at the Env-EL9 epitope selecting the L592R mutation. By IFN-γ ELISpot and immune phenotype, we characterized HLA- B*14:02 HIV-1 CD8 + T cell responses targeting, Gag-DA9 and Env-EL9 epitopes before and after LVC. We observed an immunodominant response against the Env-EL9 epitope and a decreased of the CD8 T + cell response over time with LVC. Loss of Env-EL9 responses was concomitant with selecting K588R + L592R mutations at Env-EL9. Finally, we evaluated the impact of Env-EL9 escape mutations on HIV-1 infectivity and Env protein structure. The K588R + L592R escape variant was directly related to HIV-1 increase replicative capacity and stability of Env at the LVC. Conclusions These findings support the contribution of immunodominant Env-EL9 CD8 + T-cell responses and the imposition of immune escape variants with higher replicative capacity associated with LVC in this LNTP. These data highlight the importance of Env-EL9 specific-CD8 + T-cell responses restricted by the HLA-B*14:02 and brings new insights into understanding long-term HIV-1 control mediated by Env mediated CD8 + T-cell responses., Instituto de Salud Carlos III | Ref. PI13/02269, Instituto de Salud Carlos III | Ref. PI17/00164, Instituto de Salud Carlos III | Ref. PI16/0684, Instituto de Salud Carlos III | Ref. PI19/01127, Ministerio de Economía y Competitividad | Ref. RD12/0017/0028, Ministerio de Economía y Competitividad | Ref. RD16/0025/0020, Generalitat de Catalunya | Ref. AGAUR-FI_B 00582, Agencia Estatal de Investigación | Ref. RYC-2015-18241, Agencia Estatal de Investigación | Ref. PID2019-107931GA-I00, Xunta de Galicia | Ref. ED431F 2018/08, Ministerio de Economía y Competitividad | Ref. RD16/0025/0041
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Persistent elite controllers as the key model to identify permanent HIV remission

  • Gasca-Capote, Carmen
  • Ruiz-Mateos, Ezequiel
[Purpose of review] To summarize the heterogeneity in the elite controllers population with the aim to identify a compatible profile with a persistent HIV remission, making distinction between persistent elite controllers, people with HIV (PWHIV) who permanently maintain virological control in the absence of antiretroviral treatment (ART), and transient elite controllers, PWHIV who eventually lose virological control. For this purpose, it is important to consider the mechanisms and biomarkers that have previously been associated with the maintenance and loss of the natural virological control., [Recent findings] Transient elite controllers, before losing virological control, exhibit a distinct metabolomic, proteomic, microRNAs (miRNA), immunological and virological profile compared to persistent elite controllers. In addition to a reduced and less polyfunctional HIV-specific T-cell response, transient elite controllers show a greater proportion of intact proviruses integrated into genic regions. In contrast, persistent elite controllers display a privileged HIV-1 reservoir profile with absence of detected intact proviruses or low proportion of clonal intact proviruses preferentially integrated into genomic features associated with HIV-1 transcriptional repression., [Summary] According to previous studies, the comprehensive characterization of persistent elite controllers might be crucial to identify other PWHIV with this distinct profile as spontaneously cured., This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, FEDER, “a way to make Europe”, research contracts FI19/00083 and MV20/00057 to C.G.C. and research projects PI19/01127 and PI22/01796 to E.R.M.) and Gilead Fellowships (GLD22/00147 to E.R.M.). E.R.M. was granted by the Spanish National Research Council (CSIC)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Permanent control of HIV-1 pathogenesis in exceptional elite controllers, a model of spontaneous cure

  • Casado, Concepcion
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Pernas, María
  • Tarancon-Diez, Laura
  • Rodriguez, Carmen
  • Sanchez-Merino, Víctor
  • Vera, Mar|||0000-0002-3841-7747
  • Olivares, Isabel
  • De Pablo-Bernal, Rebeca
  • Merino-Mansilla, Alberto
  • Del Romero, Jorge
  • Lorenzo-Redondo, Ramon
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Salgado, Maria|||0000-0003-1551-7216
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Lopez-Galindez, Cecilio
Elite controllers (EC) represent a small subset of HIV-1-infected people that spontaneously control viral replication. However, natural virological suppression and absence of immune dysfunction are not always long-term sustained. We define exceptional EC (EEC) as HIV-1 subjects who maintain the EC characteristics without disease progression for more than 25 years. We analyzed three EEC, diagnosed between 1988 and 1992, who never showed signs of clinical disease progression in absence of any antiretroviral treatment. A comprehensive clinical, virological, and immunological study was performed. The individuals simultaneously exhibited ≥3 described host protective alleles, low levels of total HIV-1 DNA (<20 copies/10 6 CD4 + T-cells) without evidence of replication-competent viruses (<0.025 IUPM), consistent with high levels of defective genomes, strong cellular HIV-1-specific immune response, and a high poly-functionality index (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control

  • Moyano, Ana
  • Blanch-Lombarte, Oscar|||0000-0002-8317-7535
  • Tarancon-Diez, Laura
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Arenas, Miguel
  • Alvaro, Tamara
  • Casado, Concepcion
  • Olivares, Isabel
  • Vera, Mar|||0000-0002-3841-7747
  • Rodriguez, Carmen
  • Del Romero, Jorge
  • López-Galíndez, Cecilio|||0000-0002-2324-9584
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Prado, Julia G.|||0000-0002-5439-4645
  • Pernas, María
Long-Term Non-Progressors (LTNPs) are untreated Human Immunodeficiency virus type 1 (HIV-1) infected individuals able to control disease progression for prolonged periods. However, the LTNPs status is temporary, as viral load increases followed by decreases in CD4 + T-cell counts. Control of HIV-1 infection in LTNPs viremic controllers, have been associated with effective immunodominant HIV-1 Gag-CD8 + T-cell responses restricted by protective HLA-B alleles. Individuals carrying HLA-B*14:02 control HIV-1 infection is related to an immunodominant Env-CD8 + T-cell response. Limited data are available on the contribution of HLA-B*14:02 CD8 + T -cells in LTNPs. In this study, we performed a virological and immunological detailed analysis of an HLA-B*14:02 LNTP individual that lost viral control (LVC) 27 years after HIV-1 diagnosis. We analysed viral evolution and immune escape in HLA-B*14:02 restricted CD8 + T -cell epitopes and identified viral evolution at the Env-EL9 epitope selecting the L592R mutation. By IFN-γ ELISpot and immune phenotype, we characterized HLA- B*14:02 HIV-1 CD8 + T cell responses targeting, Gag-DA9 and Env-EL9 epitopes before and after LVC. We observed an immunodominant response against the Env-EL9 epitope and a decreased of the CD8 T + cell response over time with LVC. Loss of Env-EL9 responses was concomitant with selecting K588R + L592R mutations at Env-EL9. Finally, we evaluated the impact of Env-EL9 escape mutations on HIV-1 infectivity and Env protein structure. The K588R + L592R escape variant was directly related to HIV-1 increase replicative capacity and stability of Env at the LVC. These findings support the contribution of immunodominant Env-EL9 CD8 + T-cell responses and the imposition of immune escape variants with higher replicative capacity associated with LVC in this LNTP. These data highlight the importance of Env-EL9 specific-CD8 + T-cell responses restricted by the HLA-B*14:02 and brings new insights into understanding long-term HIV-1 control mediated by Env mediated CD8 + T-cell responses. The online version contains supplementary material available at 10.1186/s12977-022-00591-7.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Elevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control

  • Masip, Jenifer|||0000-0002-9233-5195
  • Rallón, Norma|||0000-0002-4643-247X
  • Yeregui, Elena|||0000-0003-2994-4219
  • Olona, Montserrat|||0000-0001-5303-9361
  • Resino, Salvador|||0000-0001-8783-0450
  • Benito, José Miguel|||0000-0002-7172-049X
  • Viladés, Consuelo|||0000-0002-2991-9593
  • García-Pardo, Graciano|||0000-0003-0274-6001
  • Alcami, Jose|||0000-0003-0023-7377
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Gómez-Bertomeu, Frederic
  • Vargas Laguna, Montserrat|||0000-0001-7650-0587
  • Navarro Vilasaro, Marta|||0000-0002-3784-4405
  • Oteo, José A.|||0000-0001-7080-6542
  • Pineda, Juan A.|||0000-0002-3751-0296
  • Martí, Anna
  • Alba, Verónica|||0000-0002-5925-9573
  • Vidal, Francesc|||0000-0002-6692-6186
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Rull, Anna|||0000-0002-8907-7754
Long-term elite controllers (LTECs) are a fascinating small subset of HIV individuals with viral and immunological HIV control in the long term that have been designated as models of an HIV functional cure. However, data on the LTEC phenotype are still scarce, and hence, the metabolomics and lipidomics signatures in the LTEC-extreme phenotype, LTECs with more than 10 years of viral and immunological HIV control, could be pivotal to finding the keys for functional HIV remission. Metabolomics and lipidomics analyses were performed using high-resolution mass spectrometry (ultra-high-performance liquid chromatography-electrospray ionization-quadrupole time of flight [UHPLC-(ESI) qTOF] in plasma samples of 13 patients defined as LTEC-extreme, a group of 20 LTECs that lost viral and/or immunological control during the follow-up study (LTEC-losing) and 9 EC patients with short-term viral and immunological control (less than 5 years; no-LTEC patients). Long-term viral and immunological HIV-1 control was found to be strongly associated with elevated tricarboxylic acid (TCA) cycle function. Interestingly, of the nine metabolites identified in the TCA cycle, α-ketoglutaric acid (p = 0.004), a metabolite implicated in the activation of the mTOR complex, a modulator of HIV latency and regulator of several biological processes, was found to be a key metabolite in the persistent control. On the other hand, a lipidomics panel combining 45 lipid species showed an optimal percentage of separation and an ability to differentiate LTEC-extreme from LTEC-losing, revealing that an elevated lipidomics plasma profile could be a predictive factor for the reignition of viral replication in LTEC individuals.